ALESSE (ethinyl estradiol; levonorgestrel) by Cadence Neuroscience. Approved for pregnancy. First approved in 1997.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
ALESSE is an oral contraceptive combination tablet containing ethinyl estradiol and levonorgestrel, indicated for pregnancy prevention. It is a classic combined hormonal contraceptive that works by suppressing ovulation through estrogen and progestin receptor agonism. The product is delivered as a 21-day tablet regimen.
Product is in late-stage lifecycle with approaching loss of exclusivity, signaling reduced commercial team investment and potential portfolio contraction.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Observational Trial With Leios/Alesse
ALESSE currently shows zero linked job postings, reflecting its late-lifecycle status and approaching loss of exclusivity. Career opportunities on this product are limited to defensive or maintenance roles rather than growth-oriented positions, with most activity concentrated in regulatory compliance and generic transition management.
Worked on ALESSE at Cadence Neuroscience? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.